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Signal transductionPericellular proteolysis mediated by membrane-type 1 matrix metalloproteinase (MT1-MMP) represents an
essential component of the cellular machinery involved in the dissolution and penetration of ECM barriers by
tumor cells. Although most studies on the proinvasive properties of MT1-MMP have focused on its unusually
broadproteolytic activity towards several ECM components and cell surface receptors, recent evidence indicate
that the cytoplasmic domain of the enzyme also actively participates in tumor cell invasion by regulating the
cell surface localization of MT1-MMP as well as the activation of signal transduction cascades. The
identiﬁcation of the molecular events by which the intracellular domain of MT1-MMP links proteolysis of
the surrounding matrix by the enzyme to modiﬁcation of cell function may thus provide important new
information on themechanisms bywhich this enzyme controls the invasive behavior of neoplastic cells in vivo.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Matrix metalloproteinases (MMPs, EC 3.4.24) comprise a large
family of proteolytic enzymes that play an essential function in cel-
lular processes that require coordinate dissolution of the extracellular
matrix (ECM), such as those involved in tumor invasion and
angiogenesis [1,2]. Among the twenty-ﬁve members of this family
that have been described to date, there is now considerable evidence
that MMPs that are intrinsically associated with the plasma mem-
brane, the so-called membrane-typeMMPs (MT-MMP), represent key
components involved in pericellular proteolysis and subsequent cell
locomotion [3,4]. The prototypical member of this unique subclass of
MMPs, MT1-MMP, possesses an overall domain structure similar to
secreted MMPs i.e. with a zinc-containing catalytic domain, a ﬂexible
linker peptide and a hemopexin-like domain but, unlike its soluble
counterparts, the enzyme is tethered to the cell surface by a trans-
membrane segment that terminates in a short, 20-amino acid cyto-
plasmic domain [3,5]. The simultaneous presence of an extracellular
protease domain and of an intracellular juxtamembranous sequence
within the structure of MT1-MMP may thus confer this enzyme with
the unique ability to modify the surrounding extracellular matrix
environment by proteolysis as well as to closely interact with the
intracellular transduction machinery involved in the cell response to
extracellular signals.s for Health Research to R.B.
1; fax: +1 514 987 0246.
eau).
ll rights reserved.Several studies performed during the last decade have provided
strong evidence that MT1-MMP plays an essential role in both physio-
logical and pathophysiological processes. In mice, MT1-MMP deﬁ-
ciency resulted in craniofacial dysmorphism, arthritis, osteopenia,
dwarﬁsm, ﬁbrosis of soft tissues and premature death [6,7], emphasi-
zing the importance of MT1-MMP-mediated ECM degradation during
development. The activity of MT1-MMP is however stringently
regulated during subsequent maturation due to the existence of
multiple levels of transcriptional and posttranscriptional regulatory
mechanisms that control the expression, activity as well as the sub-
cellular localization of the enzyme [8–10]. The importance of these
regulatory mechanisms for the maintenance of normal cell function is
well illustrated by several studies showing elevated expression of
MT1-MMP in a wide variety of human cancers, including those of the
lung, colon, liver, breast, brain, head and neck, ovary, and uterine
cervix [11–13], reﬂecting the crucial role of MT1-MMP for efﬁcient
invasion of ECM barriers by tumor cells [14,15]. The understanding of
the molecular and cellular mechanisms involved in the up-regulation
of MT1-MMP expression and activity by cancer cells as well as of those
by which this proteolytic activity is integrated in order to sustain their
invasion and proliferation within surrounding ECM may thus provide
important new insights for the development of novel anticancer
therapeutics that control tumor progression through interference
with MT1-MMP function.
Herein, we review emerging evidence indicating that in addition to
the essential role of MT1-MMP-mediated pericellular proteolysis in
the invasion of ECM by tumor cells, the cytoplasmic domain of the
enzyme exerts an important inﬂuence on these properties by regu-
lating its cell surface localization as well as the activation of intra-
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cellular pathways may thus represent an attractive alternative
strategy to inhibit tumor progression triggered by this crucial enzyme.
2. Role of the cytoplasmic domain in the cell surface localization
of MT1-MMP
2.1. Membrane anchoring of MT1-MMP is essential for its proinvasive
properties
MT1-MMP displays an unusually broad substrate diversity for ECM
proteins, hydrolyzing proteins as diverse as collagen types I, II and III,
ﬁbrin, laminins-1 and -5, ﬁbronectin, vitronectin and aggrecan [16,17]
as well as tumor cell surface-associated receptor molecules such as
CD44 [18], tissue transglutaminase [19], the low density lipoprotein
receptor-related protein (LRP) [20], αv integrin subunit [21] and the
integrin-associated protein syndecan-1 [22] (for a review, see [23]).
Thus, the expression of MT1-MMP at the cell surface creates a broad
proteolytic repertoire in the pericellular space that results in the
modiﬁcation of a number of tumor cell functions, including migration
[24–26], invasion of ECM barriers [14,27] as well as sustained
proliferation in otherwise growth-restrictive three-dimensional (3D)
type I collagen or ﬁbrin matrices [28].
In spite of this large proteolytic repertoire and of the robust
proteolytic activity of engineered soluble forms of the enzyme [16,17],
several studies indicate that MT1-MMP-mediated proteolysis is not
sufﬁcient per se for efﬁcient penetration of ECM barriers and that
localization of the enzyme at the cell surface is essential to translate its
proteolytic activity into a modiﬁcation of cell function. For example,
while overexpression of wild type MT1-MMP confers cells with the
ability to invade collagen of ﬁbrin gels, constitutive secretion of the
enzyme following deletion of its transmembrane domain completely
abolishes this process [27,29]. In a similar manner, whereas a plethora
of studies indicate that membrane-tethered MT1-MMP induces
migration of a variety of cell types [18,30–39], the soluble version of
the enzyme failed to do so [32]. The importance of cell surface-
associated MT1-MMP activity is also well illustrated by the observa-
tion that cells overexpressing MT1-MMP mutants in which the
transmembrane domain is replaced with the GPI anchor of MT6-
MMP retain the ability to invade 3D collagen gels [40] and to sustain
cell proliferation within these matrices [41]. Unexpectedly, the
expression of a MT1-MMP chimera in which the catalytic domain of
the enzyme is replacedwith that of an unrelated collagenase (MMP-1)
also confers cells with signiﬁcant collagen-invasive properties [40],
indicating that the central function of MT1-MMP in tumor cell inva-
siveness is not solely due to its proteolytic activity but also strongly
relies on its appropriate localization at the plasma membrane of
migrating cells.
Although the above-mentioned studies may suggest at ﬁrst sight
that the participation of the transmembrane and cytoplasmic
domains of MT1-MMP to the proinvasive properties of the enzyme
is solely related to their role in the tethering of the protease to the cell
surface, numerous studies indicate that these domains may play a
more complex role in the regulation of the proteolytic activity of
MT1-MMP. For example, a MT1-MMP chimera in which the expres-
sion of the enzyme at the cell surface is achieved by fusing its
extracellular sequence to the transmembrane and cytoplasmic
segments of the interleukin-2 receptor retains the ability to activate
exogenous proMMP-2 [42] but showed impaired cell surface
localization and degradation of the ECM [43]. The cytoplasmic
domain of MT1-MMP seems to be of prominent importance in
linking the enzyme proteolytic activity to efﬁcient cell migration and
invasion since several studies have shown that deletion of this
domain has no inhibitory effect on the cell surface proteolytic activity
of the enzyme but markedly reduces cell migration triggered by the
enzyme [32,37,39,44]. As discussed below, this regulatory function ofthe cytosolic sequence of MT1-MMP stems from the participation of
this domain to processes governing the polarized localization of the
enzyme at the cell surface.
2.2. Cytoplasmic domain-dependent endocytosis of MT1-MMP
The initial response of cells to migration-promoting agents is to
polarize and extend membrane protrusions in the direction of
migration [45]. These protrusions, such as lamellipodia or invadopo-
dia, contain a diversiﬁed arsenal of proteins involved in cell adhesion,
proteolytic degradation of the ECM as well as signal transduction that,
collectively, confer cells with the ability to migrate and invade ECM
barriers [46]. Interestingly, studies have shown that migrating cells
relocalize MT1-MMP to lamellipodia and invadopodia [43,47–50]
where the enzyme interacts with key adhesion receptors, such as
CD44 [47], or with signal-transducing intermediates such as cortactin
[51] or the adaptor protein p130Cas [52].
There is now considerable evidence that the redistribution of MT1-
MMP to these sites of ECM degradation is highly complex and involves
a dynamic interplay of endocytic [53–55] and exocytic [56,57]
trafﬁcking events. Following its synthesis and maturation in the
trans-Golgi complex [58], MT1-MMP is rapidly translocated to the
plasma membrane [59] through Rab8- [57], VAMP7- [56] and
microtubule-dependent [50,53] processes, resulting in the polarized
localization of the protease to invasive structures [56,57]. However,
cell surface expression of MT1-MMP is usually very weak in most cell
types due to the rapid endocytosis of the enzyme from the plasma
membrane that results in its intracellular localization to early and late
endocytic structures [53,55,59]. This dynamic regulation of cell sur-
face expression and localization of MT1-MMP in migrating cells thus
suggests that the spatiotemporal regulation of the recruitment of the
protease to specialized domains involved in motility and invasion
plays an essential role in its proinvasive properties.
There is mounting evidence that the cytoplasmic domain of MT1-
MMP plays an important role in the regulation of its internalization
and redistribution at the plasma membrane. Numerous studies have
shown that overexpression of cytoplasmic tail-deleted forms of MT1-
MMP results in higher expression levels of the enzyme at the cell
surface, as reﬂected by enhanced activation of the MMP-2 zymogen
[39,55], this behavior being related to a markedly reduced inter-
nalization rate compared to the wild type enzyme [40,54,55].
Importantly, defective endocytosis of MT1-MMP induced by C-
terminal truncation impairs the localization to the leading edge of
migrating cells [39,43,50]. The requirement of the cytoplasmic
domain for efﬁcient MT1-MMP endocytosis is related, at least in
part, to an interaction of the 571LLY573 sequence of this domain with
the μ2 subunit of adaptor protein 2, a key component of clathrin-
coated vesicles [54]. Most interestingly, disruption of this interaction
following site-directed mutagenesis of this structural region or
through deletion of the entire cytoplasmic domain results in
decreased cell migration, suggesting that regulated endocytosis of
MT1-MMP is essential for efﬁcient cell locomotion triggered by this
enzyme [54]. Thus, although endocytosis has been traditionally con-
sidered as a mechanism that can achieve attenuation of the function
of cell surface membrane proteins by committing the internalized
proteins to degradation, regulated internalization of MT1-MMP
appears to be of prominent importance for the spatiotemporal
regulation of the enzyme's activity at the cell surface. Since
exocytosis of the enzyme seems unaffected by the truncation of the
cytosolic sequence [40], the control of cell surface expression and
localization of MT1-MMP by its cytoplasmic domain occurs pre-
dominantly through regulation of endocytosis-mediated internaliza-
tion of the enzyme.
Although endocytosis of MT1-MMP occurs primarily through
clathrin-dependent mechanisms [53,55], a signiﬁcant proportion of
the enzyme is associated with caveolae [53,60–62] which are small,
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tant roles in signal transduction processes [63] as well as in the
endocytosis of a variety of proteins [64]. A number of studies have
suggested that cell surface relocalization of the enzyme mediated by
caveolae-dependent mechanisms may contribute to the regulation of
its promigratory properties [53,65]. However, transient and regulated
association of MT1-MMP with these membrane domains seems to be
important for appropriate invasion mediated by the enzyme since
overexpression of the cytoplasmic tail-deleted form of MT1-MMP
resulted in an increased association of this mutant with caveolae that
correlates with impaired internalization and reduced cell migration in
vitro and tumor growth in vivo [66]. Such an inhibitory function of
caveolae in the regulation of MT1-MMP function is also suggested by
the predominant localization of the 44-kDa proteolytically inactive
form of the enzyme in these domains [53,60]. Interestingly, recent
studies suggest that this 44-kDa form may regulate the endocytosis
rate of the active enzyme, possibly by competing for components of
the endocytic machinery [67]. It is thus plausible that the cytoplasmic
domain-dependent interaction of MT1-MMP with other caveolae-
resident protein would be required to allow appropriate internaliza-
tion of the enzyme. In this respect, it is noteworthy that endocytosis
via caveolae is critically dependent on stimulation of tyrosine kinase
signaling, including Src-induced phosphorylation of caveolin-1 at
Tyr14 [68]. Since MT1-MMP speciﬁcally interacts with tyrosine
phosphorylated caveolin-1 in Src-expressing cells (see below) [62],
this interaction could thus participate in regulated caveolae-mediated
internalization of the enzyme.
3. MT1-MMP as a signal-transducing metalloproteinase
3.1. Activation of signal transduction cascades by MT1-MMP
There is increasing evidence that the participation of the cyto-
plasmic sequence of MT1-MMP in the proinvasive properties of the
enzyme may also involve a role of this domain in the activation of a
number of signal transduction events. Insights for such a role were
initially provided by studies showing that overexpression of MT1-
MMP induced the activation of the ERK cascade [32]. Pharmacolo-
gical blockade of ERK activation was correlated with the inhibition of
MT1-MMP-dependent cell migration induced by serum [32] or the
chemoattractant sphingosine-1-phosphate [37,69], strongly suggest-
ing the participation of this signaling cascade to cell locomotion
triggered by the enzyme.
The adhesion of cells to the ECM appears important for this
process since ERK activation was observed in cells plated on dena-
tured type I collagen but abolished in cells grown in suspension or on
poly-L-lysine-coated culture dishes [32]. In a similar manner,
adhesion of HT1080 cells to type I collagen was found to induce
MT1-MMP-dependent ERK activation, leading to subsequent cell
migration [70]. This latter group also showed that lysis of the
extracellular matrix by MT1-MMP induced focal adhesion turnover
and subsequent ERK activation, which in turn stimulates cell
migration [71]. This matrix requirement, as well as the well described
activation of the ERK cascade in response to integrin-mediated cell
adhesion [72], suggests a potential role of integrins in the regulation
of MT1-MMP activity. This is supported by the colocalization of some
integrins with the protease in migratory structures [48] and their
regulation of MT1-MMP function [73,74], possibly via the activation
of the MT1-MMP/integrin complex by Mss4 (mammalian suppressor
of Sec4), a guanine nucleotide exchange factor speciﬁc for exocytic
Rab GTPases [75].
The structural determinants of MT1-MMP responsible for its sti-
mulatory effect on the ERK cascade remain to be ﬁrmly established.
Initial experiments showed that ERK activation was abolished in cells
overexpressing the catalytically-inactive E240A mutant or the
cytoplasmic domain-deleted forms of the enzyme, suggesting theparticipation of both domains in this process [32]. In MCF-7 cells, the
addition of physiological concentrations of TIMP-2 resulted in a
protease-independent MT1-MMP-dependent activation of the Ras–
MEK–ERK signaling cascade that was strictly dependent on the
presence of the cytoplasmic sequence of the enzyme [76]. Such a
requirement of the intracellular domain is interesting since it would
suggest that defective activation of ERK observed following deletion of
this sequence could be related to alteration of the internalization of
the enzyme, as described for several growth factor receptors [77]. In
this respect, it is noteworthy that the structural region of MT1-MMP
previously reported to participate in endocytosis (571LLY573) overlaps
with that involved in ERK activation 573YCQR576 [76].
The importance of the cytoplasmic domain for activation of the
ERK cascade remains however unclear since other studies have
reported that overexpression of cytoplasmic domain-deleted MT1-
MMP activates ERK and sustains VSMC proliferation [78]. Under these
conditions, stimulation of ERK phosphorylation was shown to involve
activation of the PDGF receptor, a requirement that is related to MT1-
MMP-mediated proteolysis of the multifunctional LDL receptor-
related protein LRP1 and subsequent internalization of a PDGFR–β3in-
tegrin–MT1-MMP–LRP1 complex [79]. Such a participation of recep-
tor tyrosine kinases to MT1-MMP-mediated ERK activation is also
suggested by studies showing that overexpression of MT1-MMP
induces transactivation of the EGF receptor and that this process is
essential to cell migration [80]. By contrast to the requirement for the
PDGF receptor, however, MT1-MMP- and EGFR-dependent activation
of ERK, as well as of cell migration, were found to require the cyto-
plasmic domain of the enzyme. The reasons for the differential
requirement of proteolysis, cytoplasmic signaling as well as receptor
tyrosine kinase transactivation for efﬁcient ERK activation by MT1-
MMP in different cell systems remain unclear but possibly reﬂect the
complexity of this process and its sensitivity to the very distinct
experimental conditions used in these cellular assays.
Although most studies performed so far on the signaling pathways
that are activated downstream of MT1-MMP have focused on the ERK
cascade, it should be noted that recent studies have suggested that the
enzyme may have the ability to trigger the activation of additional
signaling pathways. For example, stimulation of corneal ﬁbroblast cell
lines deﬁcient for MT1-MMP with bFGF markedly inhibits the acti-
vation of the JNK and p38 MAP kinases as well as secretion of VEGF by
these cells, implying a role of the enzyme in the modulation of the
bFGF signaling pathway [81]. Given the ubiquitous role of ERK, p38
and JNK pathways in signal transduction events, the stimulation of
these cascades by MT1-MMP strongly suggests that the enzyme
actively participates in these processes.
3.2. MT1-MMP-interacting proteins
Since MT1-MMP lacks known recognition motifs for tyrosine
kinases (R/K/Q)X2–4(D/E)X2–3pY) or binding motifs for either Src
homology(SH)2 (pYXX(I/L)) or SH3 (PXXP) domains that would
facilitate recruitment of tyrosine kinases and signaling proteins, the
mechanisms involved in the activation of signaling cascades by the
enzyme remain obscure. However, in spite of this lack of signal-
transducing domains, several studies indicate that MT1-MMP associ-
ates with a variety of membrane-associated and cytosolic proteins
[47,48,52,62,78,82–86]. The best documented example of these
interactions is the association of MT1-MMP with the hyaluronan
receptor CD44 at migrating structures of tumor cells [47]. MT1-MMP
physically interacts with this receptor through its hemopexin domain,
leading to the cleavage of CD44 and enhanced cellmigration [18]. Since
CD44 interactswith ﬁlamentous actin through its cytoplasmic domain,
a process that is mediated by ERM (ezrin/radixin/moesin) proteins,
the binding of MT1-MMP to the receptor indirectly links the protease
to the cytoskeleton and thus enables its focal localization to
lamellipodia [47]. Recently, in vitro surface plasmon resonance analysis
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theMT1-MMP cytoplasmic domainwith the N-terminal FERMdomain
of radixin [87], raising the possibility that the protease may also have
the intrinsic ability to directly interact with the cytoskeleton.
Given the crucial role of the cytoplasmic domain of MT1-MMP in
the regulation of its cell surface expression, the identiﬁcation of pro-
teins that speciﬁcally associate with this domain is of particular
interest. In addition to the μ2 subunit of adaptor protein 2 [54]
discussed above, pull down and two hydrid techniques subsequently
showed that the intracellular domain of MT1-MMP interacts with
gC1qR [82], the receptor for the C1 complex of the classical pathway of
complement activation and MTCBP-1, a 19-kDa protein that possibly
acts as a regulator of the methionine salvage pathway [83]. However,
the multiple cellular functions performed by these proteins make
their contribution to MT1-MMP-dependent cell migration and/or
invasion still elusive. More recently, it was reported that in Src-
overexpressing cells, MT1-MMP speciﬁcally associates with the
tyrosine phosphorylated form of caveolin-1 [62], a 21-kDa membrane
protein that acts as the predominant structural component of caveolae
membrane domains. Caveolin-1 was ﬁrst identiﬁed as a major tyro-
sine phosphorylated protein in v-Src transformed embryo ﬁbroblasts
[88] and has since emerged as an important scaffolding protein that
interacts with multiple proteins involved in signal transduction, cell
adhesion and migration as well as in cell survival [89]. Interestingly,
the phosphorylated form of caveolin-1 is associated with integrins at
focal adhesions [90], raising the possibility that phosphorylated
caveolins contribute to cell attachment and migration [91]. Accord-
ingly, phosphorylation of caveolin-1 leads to its polarized accumula-
tion at the leading edge of migrating endothelial [92] as well as tumor
cells [93]. Since the association of MT1-MMP with phosphorylated
caveolin-1 was also observed following stimulation of endothelial
cells with chemoattractants such as S1P or VEGF, this suggests that
this molecular interaction may contribute to cell locomotion triggered
by these angiogenic cytokines.
It is also noteworthy that MT1-MMP is among the few proteins
identiﬁed to date that speciﬁcally interact with the tyrosine
phosphorylated form of caveolin-1 and, by analogy to the involvement
of these phosphocaveolin-binding proteins in signal transduction
processes, it is tempting to speculate that this interaction may be
important for the proinvasive properties of MT1-MMP. For example,
interaction of phosphocaveolin-1 with the C-terminal Src kinase
(Csk), a negative-regulator of Src family kinases, leads to its trans-
location into caveolae and may thus be involved in the inactivation of
the caveolar forms of these enzymes [94]. Tyrosine phosphorylated
caveolin-1 also speciﬁcally associates with growth factor receptor-
bound protein 7 (Grb7) [95], an SH2-domain adaptor protein that
links receptor tyrosine kinases to the Ras pathway [96] and that was
reported to be involved in growth factor-induced cell migration [97].
Since MT1-MMP interacts with the phosphorylated but not with the
native form of caveolin-1, it is possible that this speciﬁc association
reﬂects a similar participation to intracellular signaling cascades
underlying cell locomotion.
MT1-MMP lacks consensus caveolin-1 binding motifs (ψXψXXXXψ
and ψXXXXψXXψ, where ψ is an aromatic amino acid Trp, Phe or Tyr)
[98] in its cytoplasmic domain, suggesting that its association with
phosphocaveolin is likely to involve additional proteins. In this
respect, preliminary evidence from our laboratory indicate that upon
overexpression of Src in COS-7 cells, the cytoskeletal associated
protein paxillin associates with tyrosine phosphorylated caveolin-1
and that this complex could be involved in the recruitment of MT1-
MMP (D. Gingras, E. Béliveau and R. Béliveau, unpublished results).
Alanine scanning mutagenesis indicates that the formation of the
MT1-MMP/phosphocaveolin-1 complex involves the cysteine residue
as well as the C-terminal DKVmotif located in the cytoplasmic domain
of the enzyme, suggesting that these regions contain structural
information that enable the interaction of MT1-MMP with theseintermediary proteins [62]. Interestingly, the DKV sequence present
at the C-terminus of several proteins, including MT1-MMP, was
previously identiﬁed as a ligand for the PDZ domain of neuronal
nitric oxide synthase [99]. Since PDZ domains that recognize these
(D/E)Xψ motifs (where ψ is an hydrophic amino acid) have been
shown to mediate several protein–protein interactions [100], this
suggests that this region could be involved in the formation of
molecular complexes containing MT1-MMP. This hypothesis is
supported by the observation that the C-terminus of MT5-MMP,
that also contain this binding motif (EWV), interacts with X11γ/
Mint3 [101], a PDZ domain-containing adaptor protein that mediates
the assembly of functional multiprotein complexes [102], as well as
with two PDZ-containing proteins of the postsynaptic density in
neurons [103] and in both cases these interactions may participate to
the trafﬁcking of the enzyme [101,103].
It is also noteworthy that posttranslationally modiﬁcation of
juxtamembranous cysteine residues by palmitoylation have been
proposed to trigger the speciﬁc association of transmembrane
proteins lacking signaling motifs with proteins involved in signal
transduction [104]. Since MT1-MMP was reported to be palmitoylated
on Cys574 [105] and that mutation of this residue reduces the
association of the protease with phosphocaveolin-1 [62], this
hypothesis also warrants further investigation.
Overall, the recognition of MT1-MMP as a cell surface protease that
associates with both cell surface ECM receptors [18,48], receptor
tyrosine kinases [78] and various tetraspanins [84,85,106] as well as
with intracellular signaling proteins such as phosphocaveolin-1 and
p130Cas [52] lends credence to the hypothesis that the transmem-
brane topology of the enzyme imbues the protease with the unique
ability to inﬂuence both the extracellular remodeling of the matrix
surrounding tumor cells as well as intracellular signaling events
involved in cell invasion.
3.3. Modulation of gene transcription by MT1-MMP
There is increasing evidence that cytoplasmic domain-dependent
activation of signaling cascades by MT1-MMP may inﬂuence cell
function through modulation of gene transcription. Reporter assays
performed on cells overexpressing MT1-MMP showed that activation
of the ERK cascade was correlated with increased transcription under
the control of the serum response element (SRE) [32]. Similar to the
activation of the ERK cascade, this stimulatory effect required the
catalytic activity as well as the cytoplasmic domain of the enzyme,
suggesting that activation of signal transduction pathways by the
enzyme may lead to gene transcription.
Activation of the transcription program by MT1-MMP is also
suggested by the marked increase in the production of VEGF by tumor
cells overexpressing the enzyme [107–109], an up-regulation that is
correlated with enhanced tumor growth rates in animals as well as
elevated levels of angiogenesis [107,108]. Increased VEGF synthesis
requires the catalytic activity as well as the cytoplasmic region of the
enzyme since deletion of the six C-terminal amino acids of the
cytoplasmic domain or mutation of Cys574 completely abolished
MT1-MMP-dependent up-regulation of the VEGF gene [109]. Phar-
macological blockade of tyrosine kinase activity suggests that the
signaling pathway linking the cytoplasmic domain of MT1-MMP to
VEGF gene transcription may involve Src activity, raising the inte-
resting possibility that Src-dependent association of MT1-MMP with
caveolin-1 [62] and/or phosphorylation of the unique tyrosine residue
located in its cytoplasmic domain (see below) [110] may participate in
activation of VEGF synthesis by the enzyme. Since endothelial cell-
associated MT1-MMP also actively participate in angiogenesis
[29,37,111–113] the transcriptional activation of VEGF by the enzyme
in tumor cells suggests that the modulation of neovascularization by
MT1-MMP represents a key mechanism underlying the crucial role of
this enzyme in tumor progression.
Fig. 1. Alignment of the cytoplasmic sequences of transmembrane MT-MMPs. “+” and
“⁎” indicate basic and hydrophobic residues, respectively.
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expression suggests that the transcription of several additional genes
is under the control of the enzyme. For example, ablation of MT1-
MMP resulted in a marked down-regulation of Smad1 that was
correlated with reduced tumor growth [114]. In a similar manner,
silencing of MT1-MMP expression in human urothelial cell carcinoma
cell lines resulted in a marked increased in the levels of the tumor
suppressor Dickkopf-3 [115], suggesting that repression of this
protein by MT1-MMP may participate in the invasive properties of
these cells. Recently, a genome-wide expression proﬁling of MT1-
MMP-overexpressing versus MT1-MMP-silenced cancer cells
revealed the existence of a gene network whose expression is
strongly associated with MT1-MMP levels [116]. These genes in-
cluded regulators of energy metabolism, trafﬁcking and membrane
fusion, signaling and transcription, chromatin rearrangement, cell
division, apoptosis and mRNA splicing [116]. The identiﬁcation of the
signaling pathways linking MT1-MMP activity to the transcription of
these genes should provide crucial information on the mechanisms
by which pericellular proteolysis by the enzyme modulates the
invasive properties of tumor cells.
3.4. Tyrosine phosphorylation of the cytoplasmic domain of MT1-MMP
Additional insights for a role for the cytoplasmic domain of MT1-
MMP in the regulation of the proinvasive properties of the enzyme
may come from the observation that the unique tyrosine residue in
the MT1-MMP's cytoplasmic sequence is phosphorylated in a Src-
dependent manner and that this event likely plays an important role
in cell migration [110]. Overexpression of a non phosphorylable MT1-
MMP (Y573F) mutant markedly reduced cell migration induced by
serum or by S1P in cells that endogenously express the enzyme,
suggesting that the mutant acts in a dominant-negative manner.
Interestingly, upon stimulation of EC with S1P, MT1-MMP is relo-
calized to actin-rich membrane rufﬂes where it interacts with the
tyrosine phosphorylated form of the adaptor protein p130Cas [52].
Although the participation of phosphorylation of MT1-MMP to this
interaction remains to be ﬁrmly established, the large majority of
tyrosine phosphorylated MT1-MMP was found to colocalize with
p130Cas at cell protrusions under thesemigratory conditions, strongly
suggesting a crucial role of phosphorylation of the intracellular
domain of MT1-MMP in this process.
The importance of tyrosine phosphorylation of MT1-MMP is how-
ever not restricted to cell migration since ﬁbrosarcoma cells stably
transfected with the non phosphorylable MT1-MMP point mutant
showed markedly impaired proliferation activities within 3D but not
on 2D type I collagen gels [117]. This inhibitory effect was not related
to defective proteolytic activity of MT1-MMP since cells overexpres-
sing the mutant showed slightly higher cell surface expression of the
enzyme as well as an increased proteolytic activity towards proMMP-
2 and ﬁbrillar collagen [117]. This raises the interesting possibility that
the proteolytic activity of MT1-MMP, although essential for the
degradation of collagen barriers, may not be sufﬁcient per se to sustain
the proliferation of tumor cells within a 3D environment and that this
process would also require signals originating from the phosphory-
lated intracellular domain of the enzyme. The reduction of cyclin D3
and CDK4 levels as well as the increase in p16INK4a induced by the
expression of the non phosphorylable MT1-MMPmutant may suggest
an involvement of the tyrosine phosphorylated form of the protease in
cell cycle progression [117].
It should be noted however that these observations stand in
contrast to several studies showing that overexpression of a cyto-
plasmic domain-deleted MT1-MMP mutant in otherwise invasion-
incompetent cells induces proliferation and invasion activities similar
to those achieved following expression of the wild type enzyme
[15,27,28,40]. Although this discrepancy remains to be solved, it may
be related to differences in the intrinsic invasion program of therecipient cells used in these studies. For example, in cells that endo-
genously express MT1-MMP (such as ﬁbrosarcoma cells), the
presence of a non phosphorylable dominant-negative MT1-MMP
mutant impairs tyrosine phosphorylation of the endogenous MT1-
MMP pool, inducing competition for the activation of the cell auto-
nomous invasion program. This competition would lead to reduced
cell cycle progression and proliferation, notwithstanding adequate
proteolysis of the surrounding 3D matrix. By contrast, in invasion-
incompetent cells, pericellular proteolysis induced by overexpression
of the cytoplasmic domain-deleted mutant would be sufﬁcient to
release the growth constraints induced by the 3D environment and
confer cells with in a 3D growth advantage. Whether this cell type
speciﬁcity may also reﬂect differences in the extent of tyrosine
phosphorylation of MT1-MMP or its modiﬁcation by other posttran-
slational modiﬁcations such as palmitoylation [105] of threonine
phosphorylation [118] remains to be established.
4. Future directions
Merely 15 years following its identiﬁcation as a cell surface recep-
tor and activator of the proMMP-2 zymogen [5], MT1-MMP is now
considered as one of the most important proteinases among the N180
metalloproteases encoded by the human genome [119]. However, in
spite of the remarkable progresses made by several outstanding
groups in our understanding of the enzymatic activity, substrate
speciﬁcity and tissue-invasive properties of this crucial enzyme, a
number of key questions remain to be solved in order to fully
appreciate the complexity of the cellular mechanisms responsible for
the spatiotemporal regulation of MT1-MMP-mediated pericellular
proteolysis.
First and foremost, the extent to which the cytoplasmic domain of
MT1-MMP contributes to the proinvasive properties of the enzyme
must be clariﬁed. As discussed throughout this review, this issue
remains a matter for considerable debate and we believe that much of
this discrepancy can be attributed to the very distinct cellular assays
used to address this question. By analogy to previous studies on the
role of tissue factor cytoplasmic domain in angiogenesis [120], the
generation of mice from which the MT1-MMP cytoplasmic domain
has been deleted would represent an invaluable tool to unequivocally
resolve this issue. The availability of such an in vivo system would
electrify the ﬁeld and could lead to an in depth understanding of the
crucial role of this enzyme in both physiological and pathological
processes.
Second, since the internalization and subcellular localization of the
enzyme is strongly dependent on its cytoplasmic sequence, it would
be extremely interesting to determine how posttranslational modi-
ﬁcation of this domain by tyrosine phosphorylation inﬂuences this
process. Given that this unique cytoplasmic tyrosine residue is con-
served in all known transmembrane MT-MMPs (Fig. 1), reversible
phosphorylation of this domain could constitute a central mechanism
by which the regulation of the cell surface expression of these
enzymes is achieved. In this respect, it is noteworthy that in Src-
transformed cells, FAK-dependent phosphorylation of endophilin A2
inhibited endophilin/dynamin interactions, resulting in reduced
endocytosis of MT1-MMP and increased ECM degradation [121].
Fig. 2. Schematic representation of the structural domains of MT1-MMP and their involvement in pericellular proteolysis and cell migration. Underlined residues indicate structural
regions of the cytoplasmic domain thought to be involved in endocytosis, ERK activation as well as VEGF gene transcription [54,76,109].
147D. Gingras, R. Béliveau / Biochimica et Biophysica Acta 1803 (2010) 142–150Since MT1-MMP is likely to be tyrosine phosphorylated under these
conditions [110], this event may also contribute to the regulation of
the enzyme internalization rate and to observed proinvasive proper-
ties of the Src-expressing cells.
Third, although the relationship existing between endocytosis of
the activation of intracellular signaling events and gene transcription
by the enzyme remains unclear, structural studies performed so far
indicate a signiﬁcant overlap in the regions of the cytoplasmic domain
of MT1-MMP involved in these processes (Fig. 2). It is thus possible
that these MT1-MMP-dependent intracellular events are intertwined
and share a common dependence on appropriate internalization of
the enzyme. Accordingly, trafﬁcking membranes have been suggested
to represent an efﬁcient way to deliver messages to biologically rele-
vant locations, an importance reﬂected by the inhibition of ERK
activation by various inhibitors of endocytosis [122]. Elucidation of the
relationship existing between the internalization of MT1-MMP, its
activation of ERK cascade and its unconventional subcellular localiza-
tion to centrosome [123] as well as to the cell nucleus [124] could thus
provide crucial information on the mechanisms governing the
activation of intracellular signaling events by the enzyme. Since
MT1-MMP has been shown to be internalized by both clathrin-
mediated and raft/caveolar-mediated endocytosis, it is possible that
these two routes serve different purposes, as described for a number
of plasma-membrane receptors [125]. The merging of modern trends
in proteinase biochemistry, cell biology and signal transductionwill be
required to allow a better understanding of these processes.
5. Conclusions
Transmembrane proteins with at least one transmembraneα-helix
segment account for N25% of proteins in almost every genome
sequenced so far [126], reﬂecting the crucial role of these membrane
proteins in the integration of chemical and physical signals originating
from the extracellular milieu. This importance stems from the contact
of these proteins with both the extracellular and intracellular milieus
that provide a powerful mean to precisely sense and transduce signals
necessary for adequate regulation of cell-to-cell communication,
transport of ions across membranes and energy metabolism, among
others. In this respect, experimental data available so far indicate that
the transmembrane topology of MT1-MMP may confer this enzyme
with the unique ability to profoundly inﬂuence the extracellularenvironment through remodeling of the ECM and, in parallel, actively
participate in the signaling events involved in the cell response to
these modiﬁcations.
Owing to its ECM-degrading activity and important role in tumor
progression, MT1-MMP represents an attractive drug target for
anticancer therapies. However, broad-spectrum inhibitors of MMP
activity described to date have been largely unsuccessful in clinical
trials and, in some patients, also induced musculosketal side effects
[127]. Although the exact mechanisms underlying these effects
remain incompletely understood, they may involve an inhibition of
MT1-MMP catalytic activity since mice lacking this enzyme present
severe skeletal effects [127,128]. In this context, further studies
aimed at the molecular characterization of the pathways by which
the cytoplasmic domain of MT1-MMP contributes to the proinvasive
properties of this enzyme could thus provide interesting new
targets for the development of anticancer therapeutics.
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